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Background: Disseminated intravascular coagulation (DIC) occurs in several clinical 2 
conditions, including drug therapy. We aim to investigate the association between 3 
several drug classes use and DIC onset, using the reports of Adverse Drug Reactions 4 
(ADR) collected in Vigibase, the World Health Organization database of ADR.  5 
Methods: We collected reports of drug-related DIC from 1968 to September 2015 and 6 
classified in VigiBase according to the MedDRA (Medical Dictionary for Regulatory 7 
Activities) term “Disseminated intravascular coagulation”. A disproportionality analysis 8 
using Reporting Odds Ratio (ROR) was performed.  9 
Results: Overall 4653 reports of drug-associated DIC were selected, 75.9% was serious. 10 
DIC was significantly (ROR > 1) associated with 88 drugs, mainly antineoplastic 11 
agents, antithrombotic agents and antibacterials for systemic use. Among of the most 12 
frequently reported individual drugs were dabigatran (94 reports) ROR = 1.34 (1.08 – 13 
1.67), oxaliplatin and bevacizumab both with 75 reports and ROR = 1.77 (1.38 – 2.27) 14 
and 2.02 (1.57 – 2.61), respectively.  15 
Conclusion: A considerable number of drugs widely used in the population may be 16 
associated with the potential occurrence of DIC. For many of these, the ADR is not 17 
listed. The high number of drugs involved underline the importance of evaluate this 18 
condition such as an ADR that might occur during therapy.   19 
 20 
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1. The evaluation of possible drug-induced serious syndromes is important to 24 
guarantee the patients’ safety. 25 
2. A high number of drugs widely used in the population may be associated with 26 
rare and serious adverse drug reactions.  27 
3. Clinicians should be aware of the importance to identify and report every case of 28 
suspected drug – related disseminated intravascular coagulation. 29 
4. The assessment of the association between the drug and the adverse drug 30 
reaction may result in the updating of the summary of product characteristics. 31 
5. Early detection of possible drug-induced disseminated intravascular coagulation 32 




Introduction  35 
Blood coagulation is a physiological process put in place by the body during particular 36 
conditions; blood has to preserve its fluidity within vascular system but at the same time 37 
should be able to coagulate when exposed to non – endothelial surface in vascular lesion 38 
site and also to reset its normal flow after coagulation, through fibrinolysis [1]. 39 
Dysregulation of the homeostatic pathways results in changes that may affect 40 
preponderance of fibrinolysis or blood coagulation. Disseminated intravascular 41 
coagulation consists in the co-occurrence of both these components.  Half a century ago, 42 
disseminated intravascular coagulation wasn’t known and during autopsy it was almost 43 
impossible to find evidence of vascular disorders. Only at the end of the 1970s, more 44 
was known about it and, in addition, Sparo and colleagues [2] defined the acronym DIC 45 
as “Death Is Coming”, underlying the impact that this condition has on patients’ life. 46 
DIC is a rare and serious syndrome characterized by the wide activation of coagulation 47 
process resulting in fibrin formation and consequent thrombosis of small to medium 48 
vessels [3]. At the same time, depletion of coagulation proteins and platelets brings to 49 
severe bleeding. Recent studies clarified the pathogenetic pathway of the syndrome that 50 
seems to be caused by activation of pro inflammatory cytokines, that along with 51 
suppression of anticoagulation pathway, culminate to generation of thrombin. This 52 
activation takes place from interlukin-6 (IL-6) and, indirectly, from tumor necrosis 53 
factor alfa through its influences in IL-6 activation [4]. DIC may result as a 54 
complication of serious infection such as sepsis, severe trauma, vascular disorders, 55 
obstetrical complications, toxins or cancer. Last but not least, DIC could be also 56 
considered as an adverse drug reaction (ADR) although in literature there are very few 57 
evidences in this regard [5,6]. To the best of our knowledge, no previous studies have 58 




We aimed to investigate the potential association gathered from the use of several drug 60 
classes and the onset of DIC in order to improve the knowledge about DIC as an ADR 61 
and to underline the drugs for which it should be considered. By analyzing WHO 62 
database of adverse drug reactions and through evaluation of international literature, we 63 
want to give an overview of a subject about which little is known to date. 64 
 
Methods  65 
This is a case-by-case evaluation of all the reports of disseminated intravascular 66 
coagulation reported in the Vigibase, the WHO Global Individual Case Safety Report 67 
(ICSR) database at the Uppsala Monitoring Centre. The center has received reports 68 
about individual suspected ADRs from the countries participating in the WHO 69 
Programme for International Drug Monitoring (PIDM) starting from 1968 [7]. We 70 
collected all the suspected DIC-related cases reported from 1968 to September 2015 and 71 
classified in VigiBase with the MedDRA (Medical Dictionary for Regulatory Activities) 72 
Preferred term level “disseminated intravascular coagulation” and “disseminated 73 
intravascular coagulation in newborn”. The MedDRA is a standardized medical 74 
terminology used worldwide and having a hierarchy structures in which all the ADRs 75 
are grouped in System Organ Class (SOC) by type and etiology. The maximum 76 
precision level is defined by the preferred term, which we used for the selection of our 77 
cases. Vaccines were excluded from this analysis. Only drugs reported as suspected or 78 
interacting were evaluated. Considering that more than one drug could be reported as 79 
suspected, we analyzed the reports by drug-reaction pairs and not by number of reports. 80 
We performed a duplicate chrck using a record‐linkage strategy by grouping the 81 
overlapping records in 8 key fields: country‐text, gender, age‐reaction, re‐outcome, 82 
preferred‐base name, reported‐term, onset date, and start date.  83 
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The records having 7 out of 8 overlapping information and a single missing data in the 84 
relevant key fields were considered as duplicates. We selected the drug – DIC pairs and 85 
we evaluated the disproportionality of these pairs compared to the others in the 86 
database. This analysis was performed using the Reporting Odds Ratio (ROR) with 95% 87 
confidence interval and p value ≤ 0.05. This is a quantitative approach based on 88 
frequency analysis of 2 x 2 contingency table, developed for evaluating drug – reaction 89 
frequency compared to reference distributions of other ones from the whole database 90 
[8].  If ROR < 1, it is assumed that we are in absence of disproportionality and the 91 
distribution of reported adverse events is the same across drugs [9]; conversely, if ROR 92 
is > 1 there is an increased frequency for the drug – reaction pair considered. Only drugs 93 
with the lower bound of the 95% CI > 1 were considered as related with the ADR 94 
considered. For each drug with a statistically significant ROR (ROR > 1, p value ≤ 0.05, 95 
lower bound 95% CI > 1), we verified if disseminated intravascular coagulation was 96 
reported in the Summary of Product Characteristics (SPCs) of the corresponding 97 
medicinal products, made available by the Italian Medicine Agency (AIFA), the 98 
European Medicines Agency (EMA) and the Electronic Medicines Compendium 99 













Descriptive analysis  102 
Analyzing reports from 1968 to December 2015 in Vigibase, we collected 4,771 103 
Individual Case Safety Report (ICSR) referred to disseminated intravascular 104 
coagulation.  After the exclusion of duplicates, 4,653 reports remained for the analysis 105 
(Figure 1). Focusing on these reports, 42.7% were related to 18 - 64 years patients, 106 
29.9% to ≥ 65 years and 8.5% to 0 - 17 years. In about 19% of the cases, age was not 107 
available. Negligible difference emerged between females and males (51.2% and 45.1% 108 
respectively), while information about gender was not available in 3.7% of the reports. 109 
Table 1 shows reports classified according to age class, number of reports (N) and 110 
gender for each class. About “seriousness” criteria, we applied ICSRs standards and out 111 
of 4653 reports, 75.9% was classified as serious, while only 1.25% was not serious. 112 
Seriousness was missing in 1066 (22.9%) reports. The highest number of serious cases 113 
on the total amount of reports per class was detected in ≥ 65 years class (1104 out of 114 
1391, 79.4%). Considering “serious” cases, 1938 (54.9%) had a fatal outcome. Of these, 115 
38.4% (697 of 1938) occurred in 18 – 64 years class, 36.0% (697 of 1938) in elderly 116 
and 7.6% (147 of 1938) in 0 – 17 years class. The mortality rate, calculated on the total 117 
number of reports per age class were: 36.8% in the 0 – 17 years class, 37.4% in the 18 – 118 
64 years class and 50.1% in the elderly. Table 1 also shows “seriousness” classification 119 
and fatal outcome for each class.  120 
 121 
Disproportionality analysis 122 
Out of the total number of reports collected in Vigibase,  4,653 reports were selected 123 
applying exclusions criteria (e.g.: all duplicates with same information such as origin, 124 
gender, age or suspected drugs). In these reports, 1,111 drugs were reported as 125 
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associated with DIC. Among these, 407 drugs have been excluded because reported 126 
DIC only once and this was considered not enough to generate an alarm signal. The 704 127 
remaining drugs were reported as suspected/interacting in more than one report related 128 
to DIC. The top five drugs reported of 704 remaining were: heparin (184 reports), 129 
methotrexate (143 reports), paracetamol (117 reports), vincristine (110 reports) and 130 
cytarabine (108 reports). Eighty-eight drugs were statistically associated with DIC 131 
(ROR > 1, 95% confidence interval and p value ≤  0.05). Among these, the most 132 
frequently reported was paracetamol (117 reports), ROR [1.21 (95% CI  1.00 – 1.48)], 133 
followed by dabigatran (94 reports) ROR [1.34 (1.08 – 1.67)], oxaliplatin and 134 
bevacizumab both with 75 reports, ROR [1.77(1.38 – 2.27)] and ROR [2.02 (1.57 – 135 
2.61)] respectively. According to the ATC II level classification, the highest number of 136 
drugs reported belong to antineoplastic agents (18 drugs), antithrombotic agents (12 137 
drugs) and antibacterials for systemic use (10 drugs). Reports of antineoplastic agents 138 
(L01, 593 reports) include oxaliplatin, bevacizumab, sunitinib ROR [1.58 (1.22 – 2.06)], 139 
cisplatin ROR [1.72 (1.32 – 2.25)] and other 14 drugs; only for sunitinib DIC was an 140 
ADR reported in SPC.  As far as antithrombotic agents (B01, 290 reports), significant 141 
RORs were observed for dabigatran, drotrecogin alfa ROR [2.05 (1.58 – 2.66)], 142 
clopidogrel ROR [1.70 (1.24 – 2.32)], abiciximab ROR [2.21(1.35 – 3.62)] and other 8 143 
drugs. For all these drugs, DIC was not reported in the SPCs. Other two classes with 144 
high reporting frequency were N02 - analgesics (149 reports) and J01 - antibacterials for 145 
systemic use (102 reports). Table 2 shows the 88 drugs and the relative RORs; only 10 146 
out of 88 have DIC listed in their SPCs: sunitinib, tegafur/gimeracil/oteracil, heribulin, 147 





To the best of our knowledge, this is the first study concerning drug-induced DIC based 151 
on data of spontaneous reporting collected from Vigibase. DIC is a rare syndrome and it 152 
is even more infrequent as an ADR and evidences in literature are poor. Anyway, great 153 
attention should be paid to this ADR because in the elderly, half of the reports of 154 
adverse reactions, had a fatal outcome. The high DIC mortality rate strengths the need 155 
to understand all the possible causes and to identify all the drugs associated to it, in 156 
order to diagnose the ADR precociously. Overall, 88 drugs were statistically associated 157 
with DIC, a great number if we consider that only for 10 of them the ADR is reported in 158 
the corresponding SPC. For example, paracetamol shows a ROR > 1 in our analysis, 159 
although the lower limit of the confidence interval was CIlow95%= 1.00. The 160 
association paracetamol-DIC has been previously highlight by the Italian Medicine 161 
Agency (AIFA) in three case reports of the December 2006 bulletin [10]. Paracetamol is 162 
one of the most used drug worldwide, so it would be important to define clearly its 163 
safety profile. Also oxaliplatin and bevacizumab were between the most reported drugs.  164 
The class of antineoplastic agents deserves attention based on the several reports 165 
identified (593). A statistically significant disproportionality has been obtained with 166 
many drugs of the class such as oxaliplatin, bevacizumab, fluorouracil, irinotecan and 167 
cetuximab. Literature provides evidences regarding a case report of DIC during third-168 
line treatment with cetuximab plus irinotecan, following 5-fluorouracil, leucovorin, 169 
oxaliplatin (FOLFOX) plus bevacizumab and 5-fluorouracil, leucovorin and irinotecan 170 
(FOLFIRI) plus bevacizumab [11] that is in accordance to our data. To note that DIC 171 
could be also caused by tumor as well, both solid tumors and hematologic cancers [4], 172 
and this makes the causality assessment complicated. Another high reported class were 173 
antithrombotic/anticoagulant drugs (290 reports), in which we find a signal from the 174 
association dabigatran – DIC. A recent published article concerning efficacy and safety 175 
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of direct oral anticoagulants is in agreement with our data: the association between 176 
dabigatran and DIC has been classified as statistically significant and the author 177 
explained that it was the suspected drug in about 90% of cases [8]. In dabigatran SPC it 178 
is reported that it extends both prothrombin time and activated partial thromboplastin 179 
time, as it happens in essential laboratory tests for DIC diagnosis. None report was 180 
retrieved for other anticoagulants of the class such as rivaroxaban and apixaban. This 181 
could be due to the higher use of dabigatran in clinical practice [12,13]. The third most 182 
reported class was antibacterials agents for systemic use, but few evidences are present 183 
in literature. In general, all these three classes are also the most used drugs for the 184 
treatment of pathological conditions associated with the development of DIC. This 185 
underlines the need to carry out further studies to better understand the etiology and the 186 
possible causal association with the administration of the aforementioned drugs. 187 
Anyway, confirmations to the data of our study is given from the 10 drugs resulted to be 188 
associated with DIC, for which it is an ADR reported in the SPCs and confirmed by 189 
findings in the literature. These include sunitinib, the combination 190 
tegafur/gimeracil/oteracil, eribulin, hetastarch, rifampin, quinine, acetylsalicylic acid, 191 
dinoprostone and edaravone. Overall, considering the high mortality rate, the large 192 
number of reports retrieved and the confirmations deriving from drugs reports for which 193 
DIC is already known, we can say that it would be appropriate to carry out further 194 
analysis in order to obtain more confirmations to these possible associations identified. 195 
Only with further studies, it will be possible to guarantee the updating of the SPCs and 196 
ensure safer use of these drugs. Between the limitations of our study, stimulating 197 
reporting or under reporting represents bias in the analysis.  Underreporting widespread 198 
and it is estimated that only the 10% of ADRs occurring in everyday clinical practice 199 
are actually reported [14]. DIC underreporting could also be linked to doubts about the 200 
causality role of drugs involved. In addition, clinical information in spontaneous reports 201 
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are limited and not completed, for example co-morbidities could not be reported. DIC 202 
could also be caused by trauma, sepsis or malignancy so it is important to know every 203 
clinical information about patients in order to assess the right causality. Furthermore, 204 
the preferred term “disseminated intravascular coagulation” is highly specific and not 205 
always clinicians should use this term for report DIC in ADR reports but may use other 206 
generic terms such as coagulopathy or hematological disorders, which cause a bias in 207 
entire following analysis. Inaccuracies in the initial evaluation of clinical condition 208 
could lead to an incorrect assessment. Lastly ROR computing does not allow to quantify 209 
the actual risk of an ADR but only suggests a statistically significant association 210 
between events and drugs. The indication of a statistically significant association must 211 
be confirmed and deepened by other epidemiological studies. Nevertheless, the 212 
spontaneous reporting remains one of the simplest, low cost and essential methods for 213 
identifying ADR during post-marketing surveillance.  214 
 
Conclusion  215 
The results of our analysis highlight that a considerable number of drugs widely used in 216 
clinical practice may be associated with the potential occurrence of DIC. For many of 217 
these, the ADR is not reported in the SPC and this may be a further obstacle for the 218 
identification. The high number of drugs involved, the few evidences in literature and 219 
the great number of fatal outcome underline the importance of evaluate this condition 220 
such as an ADR that might occur during therapy. Our study provides valuable data for 221 
further analysis and clinicians should be aware of the importance to identify and report 222 
every case of suspected drug – related DIC. Studies based on spontaneous reporting, 223 
even with limitations, allow to detected ADRs after marketing authorization and 224 
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